Further phenotypic characterization of the primitive lineage- CD34+CD38- CD90+CD45RA- Hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia

Blood Cancer Journal

Volumn 1, Issue 9, 2011, Pages

  Wisniewski, D ^a   Affer, M ^a,b   Willshire, J ^a   Clarkson, B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Leukemic; Myeloid; Normal; Phenotype; Stem cells

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; CD38 ANTIGEN; CD45RA ANTIGEN; CD69 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 3 RECEPTOR; STEM CELL FACTOR;

ARTICLE; CELL CULTURE; CELL ISOLATION; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; PHENOTYPE; PROTEIN EXPRESSION;

EID: 84864030580     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.35     Document Type: Article

References (81)

1. Smith C. Hematopoietic stem cells and hematopoiesis. Cancer Control 2003; 10: 9-16. (Pubitemid 36231959)
2. Wang JC, Doedens M, Dick JE. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood 1997; 89: 3919-3924. (Pubitemid 27220934)
3. Bryder D, Rossi DJ, Weissman IL. Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am J Pathol 2006; 169: 338-346. (Pubitemid 44156296)
4. Gothot A, Pyatt R, McMahel J, Rice S, Srour EF. Functional heterogeneity of human CD34(+) cells isolated in subcompartments of the G0/G1 phase of the cell cycle. Blood 1997; 90: 4384-4393. (Pubitemid 27508444)
5. Schriber JR, Dejbakhsh-Jones S, Kusnierz-Glaz CR, Ginzton N, Still B, Negrin RS et al. Enrichment of bone marrow and blood progenitor (CD34+) cells by density gradients with sufficient yields for transplantation. Exp Hematol 1995; 23: 1024-1029.
6. Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA 1997; 94: 5320-5325. (Pubitemid 27214781)
7. Pierre-Louis O, Clay D, Brunet de la Grange P, Blazsek I, Desterke C, Guerton B et al. Dual SP/ALDH functionalities refine the human hematopoietic Lin-CD34+CD38- stem/progenitor cell compartment. Stem Cells 2009; 27: 2552-2562.
8. Christ O, Lucke K, Imren S, Leung K, Hamilton M, Eaves A et al. Improved purification of hematopoietic stem cells based on their elevated aldehyde dehydrogenase activity. Haematologica 2007; 92: 1165-1172. (Pubitemid 350144173)
9. Wisniewski D, Platsoucas C, Strife A, Lambek C, Clarkson B. Enrichment of hematopoietic progenitor cells (CFUC and BFUE) from human peripheral blood. Exp Hematol 1982; 10: 817-829. (Pubitemid 13222175)
10. Strife A, Perez A, Lambek C, Wisniewski D, Bruno S, Darzynkiewicz Z et al. Characterization of lineage-negative blast subpopulations derived from normal and chronic myelogenous leukemia bone marrows and determination of their responsiveness to human c-kit ligand. Cancer Res 1993; 53: 401-409. (Pubitemid 23031856)
11. Wisniewski D, Strife A, Arlin Z, Knowles R, Lambek C, Gulati S et al. Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia. Leukemia 1989; 3: 446-452. (Pubitemid 19145304)
12. Strife A, Lambek C, Wisniewski D, Arlin Z, Thaler H, Clarkson B. Proliferative potential of subpopulations of granulocytemacrophage progenitor cells in normal subjects and chronic myelogenous leukemia patients. Blood 1983; 62: 389-397. (Pubitemid 13036089)
13. Kim I, He S, Yilmaz OH, Kiel MJ, Morrison SJ. Enhanced purification of fetal liver hematopoietic stem cells using SLAM family receptors. Blood 2006; 108: 737-744. (Pubitemid 44061378)
14. Kent DG, Copley MR, Benz C, Wohrer S, Dykstra BJ, Ma E et al. Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. Blood 2009; 113: 6342-6350.
15. Domen J, Wagers A, Weissman IL. 'Bone marrow (hematopoietic) stem cells' in Regenerative Medicine. National Institutes of Health, U.S. Department of Health and Human Services: Bethesda, MD, 2006, pp 13-34. http://stemcells.nih. gov/info/ 2006report/2006chapter2.
16. Broxmeyer HE, Srour E, Orschell C, Ingram DA, Cooper S, Plett PA et al. Cord blood stem and progenitor cells. Methods Enzymol 2006; 419: 439-473. (Pubitemid 44820377)
17. Majeti R, Park CY, Weissman IL. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell 2007; 1: 635-645. (Pubitemid 350215330)
18. Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 1992; 89: 2804-2808.
19. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984; 133: 157-165. (Pubitemid 14076703)
20. Terstappen LW, Huang S, Safford M, Lansdorp PM, Loken MR. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood 1991; 77: 1218-1227.
21. Lansdorp PM, Sutherland HJ, Eaves CJ. Selective expression of CD45 isoforms on functional subpopulations of CD34+ hemopoietic cells from human bone marrow. J Exp Med 1990; 172: 363-366. (Pubitemid 20217280)
22. Clarkson B, Strife A, Perez A, Lambek C, Wisniewski D. Integration of molecular and biological abnormalities in quest for selective treatment of chronic myelogenous leukemia (CML). Leuk Lymphoma 1993; 11 (Suppl 2): 81-100. (Pubitemid 24024981)
23. Clarkson BD, Strife A, Wisniewski D, Lambek C, Carpino N. New understanding of the pathogenesis of CML: a prototype of early neoplasia. Leukemia 1997; 11: 1404-1428. (Pubitemid 27404379)
24. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
25. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977; 63: 125-130. (Pubitemid 8146659)
26. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
27. Mauro MJ, Druker BJ. STI571: targeting BCR-ABL as therapy for CML. Oncologist 2001; 6: 233-238. (Pubitemid 32592214)
28. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358-3363.
29. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
30. Quintas-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009; 113: 6315-6321.
31. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37. (Pubitemid 43990609)
32. Lahaye T, Riehm B, Berger U, Paschka P, Muller MC, Kreil S et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005; 103: 1659-1669. (Pubitemid 40490027)
33. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472-3475. (Pubitemid 34525335)
34. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242-2249. (Pubitemid 47523141)
35. Clarkson B, Rubinow SI. Growth Kinetics in Human Leukemia. Williams & Wilkins: Baltimore, 1977, pp. 591-628.
36. Redner RL. Why doesn't imatinib cure chronic myeloid leukemia? Oncologist 2010; 15: 182-186.
37. Barnes DJ, Melo JV. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006; 5: 2862-2866. (Pubitemid 44953936)
38. Clarkson B, Strife A, Wisniewski D, Lambek CL, Liu C. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia 2003; 17: 1211-1262. (Pubitemid 36857334)
39. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-4707. (Pubitemid 36857723)
40. Shackelford DA, Kaufman JF, Korman AJ, Strominger JL. HLA-DR antigens: structure, separation of subpopulations, gene cloning and function. Immunol Rev 1982; 66: 133-187. (Pubitemid 12001896)
41. Schlossman SF, Chess L, Humphreys RE, Strominger JL. Distribution of Ia-like molecules on the surface of normal and leukemic human cells. Proc Natl Acad Sci USA 1976; 73: 1288-1292.
42. Moore MA, Broxmeyer HE, Sheridan AP, Meyers PA, Jacobsen N, Winchester RJ. Continuous human bone marrow culture: Ia antigen characterization of probable pluripotential stem cells. Blood 1980; 55: 682-690. (Pubitemid 10138855)
43. Lu L, Broxmeyer HE, Meyers PA, Moore MA, Thaler HT. Association of cell cycle expression of Ia-like antigenic determinations on normal human multipotential (CFU-GEMM) and erythroid (BFU-E) progenitor cells with regulation in vitro by acidic isoferritins. Blood 1983; 61: 250-256. (Pubitemid 13137642)
44. Sutherland HJ, Eaves CJ, Eaves AC, Dragowska W, Lansdorp PM. Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 1989; 74: 1563-1570. (Pubitemid 19251530)
45. Sharma S, Gurudutta GU, Satija NK, Pati S, Afrin F, Gupta P et al. Stem cell c-KIT and HOXB4 genes: critical roles and mechanisms in self-renewal, proliferation, and differentiation. Stem Cells Dev 2006; 15: 755-778. (Pubitemid 46147849)
46. Roskoski Jr R. Signaling by Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 2005; 337: 1-13. (Pubitemid 41393751)
47. Kawashima I, Zanjani ED, Almaida-Porada G, Flake AW, Zeng H, Ogawa M. CD34+ human marrow cells that express low levels of Kit protein are enriched for long-term marrow-engrafting cells. Blood 1996; 87: 4136-4142. (Pubitemid 26152257)
48. Gunji Y, Nakamura M, Osawa H, Nagayoshi K, Nakauchi H, Miura Y et al. Human primitive hematopoietic progenitor cells are more enriched in KITlow cells than in KIThigh cells. Blood 1993; 82: 3283-3289. (Pubitemid 23356697)
49. Sogo S, Inaba M, Ogata H, Hisha H, Adachi Y, Mori S et al. Induction of c-kit molecules on human CD34+/c-kit o low cells: evidence for CD34+/c-kit o low cells as primitive hematopoietic stem cells. Stem Cells 1997; 15: 420-429. (Pubitemid 27513716)
50. Batard P, Sansilvestri P, Scheinecker C, Knapp W, Debili N, Vainchenker W et al. The Tie receptor tyrosine kinase is expressed by human hematopoietic progenitor cells and by a subset of megakaryocytic cells. Blood 1996; 87: 2212-2220. (Pubitemid 26086860)
51. Hashiyama M, Iwama A, Ohshiro K, Kurozumi K, Yasunaga K, Shimizu Y et al. Predominant expression of a receptor tyrosine kinase, TIE, in hematopoietic stem cells and B cells. Blood 1996; 87: 93-101. (Pubitemid 26011823)
52. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004; 118: 149-161. (Pubitemid 38962572)
53. Lindemann A, Mertelsmann R. Interleukin-3 and its receptor. Cancer Treat Res 1995; 80: 107-142.
54. Reddy EP, Korapati A, Chaturvedi P, Rane S. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene 2000; 19: 2532-2547. (Pubitemid 30339209)
55. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14: 1777-1784.
56. Tjonnfjord GE, Steen R, Evensen SA, Thorsby E, Egeland T. Characterization of CD34+ peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1994; 84: 2795-2801. (Pubitemid 24317414)
57. Andrews RG, Singer JW, Bernstein ID. Precursors of colonyforming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med 1989; 169: 1721-1731. (Pubitemid 19126828)
58. Srour EF, Zanjani ED, Cornetta K, Traycoff CM, Flake AW, Hedrick M et al. Persistence of human multilineage, self-renewing lymphohematopoietic stem cells in chimeric sheep. Blood 1993; 82: 3333-3342. (Pubitemid 23356704)
59. Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR. Blood 1998; 92: 4325-4335. (Pubitemid 28544350)
60. Yuasa H, Takakura N, Shimomura T, Suenobu S, Yamada T, Nagayama H et al. Analysis of human TIE2 function on hematopoietic stem cells in umbilical cord blood. Biochem Biophys Res Commun 2002; 298: 731-737. (Pubitemid 35356800)
61. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005; 106: 4086-4092. (Pubitemid 41775913)
62. Pearce DJ, Taussig DC, Bonnet D. Implications of the expression of myeloid markers on normal and leukemic stem cells. Cell Cycle 2006; 5: 271-273. (Pubitemid 43213496)
63. Testi R, D'Ambrosio D, De Maria R, Santoni A. The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol Today 1994; 15: 479-483. (Pubitemid 24316014)
64. Hantschel O, Gstoettenbauer A, Colinge J, Kaupe I, Bilban M, Burkard TR et al. The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia. Mol Oncol 2008; 2: 272-281.
65. Strife A, Lambek C, Perez A, Darzynkiewicz Z, Skierski J, Gulati S et al. The effects of transforming growth factor beta 3 on the growth of highly enriched hematopoietic progenitor cells derived from normal human bone marrow and peripheral blood. Cancer Res 1991; 51: 4828-4836.
66. Olofsson T, Gartner I, Olsson I. Separation of human bone marrow cells in density gradients of polyvinylpyrrolidone coated silica gel (Percoll). Scand J Haematol 1980; 24: 254-262. (Pubitemid 10113420)
67. Wisniewski D, Strife A, Clarkson B. Co-detection of chimeric bcr/abl (target) and beta-actin (control) messenger RNA in individual CFU-GM colonies derived from CML patients using the polymerase chain reaction. Leuk Res 1991; 15: 867-874.
68. Savoldo B, Sammarelli G, Dotti G, Garau D, Regazzi E, Cilloni D et al. Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells. Leukemia 1998; 12: 434-440. (Pubitemid 28138230)
69. Strife A, Wisniewski D, Liu C, Lambek CL, Darzynkiewicz Z, Silver RT et al. Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cells. Mol Cancer Res 2003; 1: 176-185. (Pubitemid 36330199)
70. Strife A, Perez A, Lambek C, Wisniewski D, Bruno S, Darzynkiewicz Z et al. Differences in the composition and in the efficiency of red cell production of normal and CML erythroid progenitor populations are highlighted by response to human c-kit ligand. Leuk Res 1993; 17: 799-807. (Pubitemid 23286843)
71. Clarkson B, Strife A. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. Leukemia 1993; 7: 1683-1721. (Pubitemid 23347286)
72. Affer M, Dao S, Liu C, Olshen AB, Mo Q, Viale A et al. Gene expression differences between enriched normal and chronic myelogenous leukemia quiescent stem/progenitor cells and correlations with biological abnormalities. J Oncol 2011; 2011: 1-25.
73. Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cyclemaintaining proteins. J Cell Biol 1993; 123: 513-522. (Pubitemid 23324910)
74. Ito M, Kobayashi K, Nakahata T. NOD/Shi-scid IL2rgamma(null) (NOG) mice more appropriate for humanized mouse models. Curr Top Microbiol Immunol 2008; 324: 53-76.
75. McKenzie JL, Gan OI, Doedens M, Wang JC, Dick JE. Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment. Nat Immunol 2006; 7: 1225-1233. (Pubitemid 44594319)
76. Muller-Sieburg CE, Sieburg HB. Clonal diversity of the stem cell compartment. Curr Opin Hematol 2006; 13: 243-248. (Pubitemid 44288900)
77. Eaves AC, Barnett MJ, Ponchio L, Cashman JD, Petzer AL, Eaves CJ. Differences between normal and CML stem cells: potential targets for clinical exploitation. Stem Cells 1998; 16 (Suppl 1): 77-83; discussion 89.
78. Petzer A, Eaves CJ, Lansdorp PM, Ponchio L, Barnett MJ, Eaves AC. Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood 1996; 88: 2162-2171. (Pubitemid 26307919)
79. Rosu-Myles M, Gallacher L, Murdoch B, Hess DA, Keeney M, Kelvin D et al. The human hematopoietic stem cell compartment is heterogeneous for CXCR4 expression. Proc Natl Acad Sci USA 2000; 97: 14626-14631. (Pubitemid 32016626)
80. Yu Y, Flint A, Dvorin EL, Bischoff J. AC133-2, a novel isoform of human AC133 stem cell antigen. J Biol Chem 2002; 277: 20711-20716. (Pubitemid 34967375)
81. Shibata FG-KY, Morikawa Y, Komori T, Ito M, Fukuchi Y, Houchins JP et al. Roundabout 4 is expressed on hematopoietic stem cells and potentially involved in the niche-mediated regulation of the side population phenotype. Stem Cells 2009; 27: 183-190.